Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629693 | 0.93 | HRH3 (0.43) | HRH3ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1627357 | 0.90 | HRH3 (0.43) | HRH3SMN1; SMN2CYP3A4POLBPPARG | |
| SCHEMBL662362 | 0.86 | PPARG (0.41) | HRH3ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4959621 | 0.81 | DUT (0.39) | HRH3ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3079743 | 0.79 | DUT (0.36) | PPARGDUT | |
| SCHEMBL25369942 | 0.78 | LTA4H (0.50) | LMNACYP3A4DUTCYP1A2CYP2D6 | |
| SCHEMBL662532 | 0.78 | DUT (0.40) | ALDH1A1SMN1; SMN2LMNAMEN1USP2 | |
| SCHEMBL1627173 | 0.77 | DUT (0.40) | ALDH1A1SMN1; SMN2LMNAMEN1USP2 | |
| SCHEMBL15827693 | 0.76 | CYP3A4 (0.44) | ALDH1A1SMN1; SMN2LMNAMEN1USP2 | |
| SCHEMBL20568979 | 0.75 | APP (0.41) | ALDH1A1SMN1; SMN2CYP3A4DUTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HRH3 3066/4885ALDH1A1 2228/4885SMN1; SMN2 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.